OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Decline in Short Interest

Posted by Francis Steltz on Jun 3rd, 2026

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Get Free Report) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totaling 162,711 shares, a decrease of 38.3% from the April 30th total of 263,628 shares. Based on an average daily trading volume, of 51,301 shares, the days-to-cover ratio is presently 3.2 days. Approximately 0.7% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on OKYO shares. Piper Sandler initiated coverage on shares of OKYO Pharma in a research report on Friday, February 20th. They issued an “overweight” rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.33.

Get Our Latest Stock Report on OKYO Pharma

Institutional Trading of OKYO Pharma

A number of institutional investors have recently modified their holdings of OKYO. Citadel Advisors LLC acquired a new stake in OKYO Pharma in the third quarter valued at approximately $31,000. Renaissance Technologies LLC lifted its stake in OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in OKYO Pharma during the fourth quarter worth $36,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Price Performance

Shares of OKYO stock opened at $1.70 on Wednesday. The firm has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.87. OKYO Pharma has a twelve month low of $1.44 and a twelve month high of $3.35.

OKYO Pharma Company Profile

(Get Free Report)

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.

Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.